DF/HCC Prostate SPORE

项目总结--总体 达纳-法伯/哈佛癌症中心(DF/HCC)前列腺癌孢子试图提高人们对 以及使用高度翻译的方法治疗前列腺癌。应用程序由三个部分组成 项目，三个核心，一个发展研究方案和一个职业提升方案。这个 孢子基础设施将促进我们蓬勃发展的基础、 致力于前列腺癌研究的临床和人口科学研究人员。每个项目都针对 这是导致前列腺癌发病率和死亡率的根本挑战。项目1利用 接受新辅助治疗的高危前列腺癌患者的肿瘤标本 了解肿瘤如何反应和抵抗急性有效雄激素受体阻断并开发新的 提高治愈率和对抗耐药性的战略。项目2将制定创新战略，以 晚期去势抵抗前列腺癌晚期的表观基因组将发展为第一个现场试验 临床试验侧重于共同靶向EZH2和PARP。项目3深入研究本地化的生物标志物 前列腺癌，利用计算和生物引导的深度学习方面的创新，提供 这种疾病状态下的精确癌症医学。能够理解为什么一些局限性的前列腺 癌症的表型是侵袭性的，并预测哪些局限性前列腺癌会在这种情况下表现 这种方式解决了大量临床上未得到满足的需求。这些项目中的每一个都将优雅的临床前工作与 由DF/HCC研究人员领导的创新临床研究。核心A，即行政核心，将成为 科学、财政和行政监督。它将领导规划和沟通方面的努力，还 成立患者权益倡导委员会。核心A将确保DF/HCC基础设施支持 孢子临床和翻译研究的努力。核心B，生物统计和计算生物学核心， 将提供生物统计以及基因组和其他下一代生物管理方面的专门知识 数据测序和数据共享。C核心，生物学家和病理学核心，将维持组织/血液 孢子项目的资料库以及前列腺癌项目中的其他研究人员。会的 提供关键的专业知识和病理服务，包括下一代分子分析，并将帮助 促进新鲜肿瘤标本的使用，包括用于患者衍生模型开发的快速尸检 以加快转化性调查。发展性研究和职业提升计划 将确定并资助解决基础、翻译和临床研究问题的创新项目，并 在前列腺癌方面未得到满足的需求，并将支持早期职业生涯和新的前列腺癌研究人员。这些 项目将积极招聘和留住来自不同背景的研究人员，以培养尖端和 有影响力的前列腺癌转化科学。我们预计DF/HCC前列腺癌孢子将使 该领域的重大科学发现，并直接转化为前列腺癌男性的益处。

PROJECT SUMMARY – OVERALL The Dana-Farber/Harvard Cancer Center (DF/HCC) Prostate SPORE seeks to improve the understanding and treatment of prostate cancer using a highly translational approach. The application consists of three Projects, three Cores, a Developmental Research Program and a Career Enhancement Program. The SPORE infrastructure will facilitate interactions and collaboration within our thriving community of basic, clinical, and population science researchers dedicated to prostate cancer research. Each project addresses a fundamental challenge that contributes to prostate cancer morbidity and mortality. Project 1 leverages tumor specimens from patients with high-risk prostate cancer treated with neoadjuvant therapies to understand how tumors respond and resist acute potent androgen receptor blockade and to develop novel strategies to improve cure rates and combat resistance. Project 2 will develop innovative strategies to target the epigenome in later stages of advanced castration resistant prostate cancer and will develop a first-in-field clinical trial focused on co-targeting EZH2 and PARP. Project 3 delves deep into biomarkers in localized prostate cancer, leveraging innovations in computation and biologically-guided deep learning, to deliver on precision cancer medicine in this disease state. The ability to understand why some localized prostate cancers are phenotypically aggressive and predict which localized prostate cancers will behave in this manner addresses a large clinical unmet need. Each of these projects combines elegant preclinical work with innovative clinical studies led by DF/HCC investigators. Core A, the Administrative Core, will be the center for scientific, fiscal and administrative oversight. It will lead efforts in planning and communication, and also house the Patient Advocacy Committee. Core A will ensure that the DF/HCC infrastructure supports the SPORE clinical and translational research efforts. Core B, the Biostatistics and Computational Biology core, will provide specialized expertise in biostatistics and the management of genomic and other next generation sequencing data and data sharing. Core C, the Biospecimen and Pathology Core, will maintain tissue/blood repositories for the SPORE projects as well as other investigators within the prostate cancer program. It will provide critical expertise and pathology services including next generation molecular assays and will help facilitate the use of fresh tumor specimens including rapid autopsies for patient derived model development to accelerate translational investigation. The Developmental Research and Career Enhancement Programs will identify and fund innovative projects that address basic, translational, and clinical research questions and unmet needs in prostate cancer and will support early career and new prostate cancer investigators. These programs will actively recruit and retain researchers from diverse backgrounds to foster cutting-edge and impactful prostate cancer translational science. We anticipate that the DF/HCC Prostate SPORE will make substantial scientific discoveries in the field and translate directly into benefits for men with prostate cancer.